Auker Biotech

Executive Summary

Auker Biotech, established in 2002 and headquartered in Wuhan, China, specializes in the development and manufacturing of high-quality monoclonal antibodies and antigens for the in-vitro diagnostic (IVD) industry. The company's core technology centers on antibody pair development, providing critical raw materials for diagnostic test kits targeting infectious diseases, tumor markers, and cardiovascular health. With ISO 13485-certified manufacturing facilities, Auker serves a growing demand for reliable, cost-effective IVD components in China and globally. The IVD market in China continues to expand, driven by increasing healthcare spending and demand for rapid diagnostic solutions. Auker is well-positioned to benefit from this trend through its established capabilities and focus on quality. Key catalysts include potential new product launches for emerging infectious diseases, international market expansion via regulatory certifications, and strategic partnerships with major diagnostic kit manufacturers. As a private, commercial-stage company with a two-decade track record, Auker offers a stable opportunity within the diagnostics supply chain.

Upcoming Catalysts (preview)

• Q3 2026Launch of new monoclonal antibody pairs for emerging infectious diseases60% success
• Q4 2026CE marking or FDA registration for expanded international sales40% success
• Q1 2027Strategic partnership with a leading IVD kit manufacturer50% success